IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS).

"Declarations Ethics approval and consent to participate {24}Approval for the trial was obtained by the Berlin statal ethics committee with reference number 22-735_1-MP Mono – IV E 17. Written informed consent will be obtained from all patients recording to GCP. All study participants are insured according to the requirements of the German Drug Law. Consent for publication {32}Not applicable. Competing interests {28}The authors declare that they have no competing interests. Competing interests {28} The authors declare that they have no competing interests."

"Funding {4} This trial is an investigator-initiated subject (IIT). The trial is part of the NKSG for therapy studies concerning ME/CFS and post COVID syndrome funded by the German Federal Ministry of Education and Research (BMBF) (grant: 01EP2201). Besides, Miltenyi Biotec company provided the apheresis units and contributed to covering the costs of financing a physician position. Funding Open Access funding enabled and organized by Projekt DEAL."

"Trial registration Registration Number: NCT05710770. Registered on 02 February 2023."